Cargando…

Antithyroid drugs

Detalles Bibliográficos
Autor principal:	Jastrzębska, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480840/ http://dx.doi.org/10.1186/1756-6614-8-S1-A12

Ejemplares similares

Antithyroid Drugs
por: Abdi, Hengameh, et al.
Publicado: (2019)

Antithyroid autoantibody population as a source of antibody specificity and functionality: clinical significance of the phenomenon of the serological orchestra in monitoring of patients with Graves' disease
por: Bogatyreva, Zemphira I, et al.
Publicado: (2014)

What is the best therapeutic approach if the initial glucocorticoids therapy of active Graves’ orbitopathy fails?
por: Jastrzębska, Helena
Publicado: (2013)

Amiodarone and the thyroid dysfunction
por: Jastrzębska, Helena
Publicado: (2013)

Toxic Effects of Antithyroid Drugs
por: Peters, J. P., et al.
Publicado: (1949)

Antithyroid drugs and birth defects
por: Andersen, Stine Linding, et al.
Publicado: (2020)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Morphea and antithyroid antibodies
por: Dańczak-Pazdrowska, Aleksandra, et al.
Publicado: (2018)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Antithyroid Drug-Induced Agranulocytosis: A Case Report
por: MacKay, Micaela, et al.
Publicado: (2023)

Effect of Antithyroid Therapies on Bone and Body Composition: A Prospective, Randomized, Clinical Study Comparing Antithyroid Drugs with Radioiodine Therapy
por: Kansara, Shekhar, et al.
Publicado: (2017)

Factors affecting drug-induced liver injury: antithyroid drugs as instances
por: Heidari, Reza, et al.
Publicado: (2014)

Frequency of Adverse Events of Antithyroid Drugs Administered during Pregnancy
por: Yoshihara, Ai, et al.
Publicado: (2014)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management
por: Vicente, Nuno, et al.
Publicado: (2017)

Antithyroid Drug-Induced Lupus Erythematosus and Immunoglobulin A Deficiency
por: Beernaert, Laetitia, et al.
Publicado: (2020)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases. Erratum
por: Singh, R. P., et al.
Publicado: (2015)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Spleen-Specific Development of Germinal Centers in Rats Treated with Antithyroid Drugs
por: Fukui, Motoko, et al.
Publicado: (2013)

Antithyroid drug induced agranulocytosis: what still we need to learn ?
por: Chaudhry, Liaqat Ali, et al.
Publicado: (2016)

The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of (131)I in Hyperthyroidism
por: Kartamihardja, A. Hussein Sundawa, et al.
Publicado: (2016)

The Effect of Thyrotropin-Releasing Hormone and Antithyroid Drugs on Fetal Thyroid Function
por: Vrachnis, Nikolaos, et al.
Publicado: (2021)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
por: Kim, Hyunsam, et al.
Publicado: (2018)

A Categorical Structure-Activity Relationship Analysis of the Developmental Toxicity of Antithyroid Drugs
por: Cunningham, Albert R., et al.
Publicado: (2009)

Antithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations
por: Dănciulescu Miulescu, R, et al.
Publicado: (2013)

Erratum: antithyroid drug induced agranulocytosis: what still we need to learn?
Publicado: (2016)

MICA polymorphisms associated with antithyroid drug‐induced agranulocytosis in the Chinese Han population
por: Gong, Xiaojuan, et al.
Publicado: (2020)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Screening and brief intervention for problems related to alcohol and other drugs between users of the Family Health Strategy
por: Abreu, Angela MM, et al.
Publicado: (2013)

Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Pressure-Tuning Raman Spectra of Diiodine Thioamide Compounds: Models for Antithyroid Drug Activity
por: Corban, Ghada J., et al.
Publicado: (2006)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Hyperthyroidism in Pregnancy: The Delicate Balance between Too Much or Too Little Antithyroid Drug
por: Gheorghiu, Monica Livia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44om8jm6oo9tpg87nlevdf7tmq